Selected research
Market Structure
Global Candesartan and Hydrochlorothiazide Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Candesartan and Hydrochlorothiazide market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Candesartan and Hydrochlorothiazide is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Candesartan and Hydrochlorothiazide is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Candesartan and Hydrochlorothiazide is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Candesartan and Hydrochlorothiazide is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Candesartan and Hydrochlorothiazide include ANI Pharmaceuticals, Dr. Reddy's Laboratories, MACLEODS, Prinston Pharmaceutical, Zydus Pharmaceuticals, AstraZeneca, Mylan and TEVA, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Candesartan and Hydrochlorothiazide market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Candesartan and Hydrochlorothiazide and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Candesartan and Hydrochlorothiazide sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Candesartan and Hydrochlorothiazide market size, projected growth trends, production technologies, key applications, and end-use industries.
Candesartan and Hydrochlorothiazide Segment by Company
ANI Pharmaceuticals
Dr. Reddy's Laboratories
MACLEODS
Prinston Pharmaceutical
Zydus Pharmaceuticals
AstraZeneca
Mylan
TEVA
Candesartan and Hydrochlorothiazide Segment by Type
16/12.5
32/12.5
32/25
Candesartan and Hydrochlorothiazide Segment by Application
Adults
Geriatric
Candesartan and Hydrochlorothiazide Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Candesartan and Hydrochlorothiazide market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Candesartan and Hydrochlorothiazide and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Candesartan and Hydrochlorothiazide.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Candesartan and Hydrochlorothiazide market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Candesartan and Hydrochlorothiazide manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Candesartan and Hydrochlorothiazide in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Candesartan and Hydrochlorothiazide in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- 16/12.5
- 32/12.5
- 32/25
Applications
- Adults
- Geriatric
Companies covered
- ANI Pharmaceuticals
- Dr. Reddy's Laboratories
- MACLEODS
- Prinston Pharmaceutical
- Zydus Pharmaceuticals
- AstraZeneca
- Mylan
- TEVA
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Candesartan and Hydrochlorothiazide Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Candesartan and Hydrochlorothiazide Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Candesartan and Hydrochlorothiazide Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Candesartan and Hydrochlorothiazide Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Candesartan and Hydrochlorothiazide Market Dynamics
- 2.1 Candesartan and Hydrochlorothiazide Industry Trends
- 2.2 Candesartan and Hydrochlorothiazide Industry Drivers
- 2.3 Candesartan and Hydrochlorothiazide Industry Opportunities and Challenges
- 2.4 Candesartan and Hydrochlorothiazide Industry Restraints
3 Candesartan and Hydrochlorothiazide Market by Manufacturers
- 3.1 Global Candesartan and Hydrochlorothiazide Revenue by Manufacturers (2021-2026)
- 3.2 Global Candesartan and Hydrochlorothiazide Sales by Manufacturers (2021-2026)
- 3.3 Global Candesartan and Hydrochlorothiazide Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Candesartan and Hydrochlorothiazide Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Candesartan and Hydrochlorothiazide Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Candesartan and Hydrochlorothiazide Manufacturers, Product Type & Application
- 3.7 Global Candesartan and Hydrochlorothiazide Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Candesartan and Hydrochlorothiazide Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Candesartan and Hydrochlorothiazide Players Market Share by Revenue in 2025
- 3.8.3 2025 Candesartan and Hydrochlorothiazide Tier 1, Tier 2, and Tier 3
4 Candesartan and Hydrochlorothiazide Market by Type
- 4.1 Candesartan and Hydrochlorothiazide Type Introduction
- 4.1.1 16/12.5
- 4.1.2 32/12.5
- 4.1.3 32/25
- 4.2 Global Candesartan and Hydrochlorothiazide Sales by Type
- 4.2.1 Global Candesartan and Hydrochlorothiazide Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Candesartan and Hydrochlorothiazide Sales by Type (2021-2032)
- 4.2.3 Global Candesartan and Hydrochlorothiazide Sales Market Share by Type (2021-2032)
- 4.3 Global Candesartan and Hydrochlorothiazide Revenue by Type
- 4.3.1 Global Candesartan and Hydrochlorothiazide Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Candesartan and Hydrochlorothiazide Revenue by Type (2021-2032)
- 4.3.3 Global Candesartan and Hydrochlorothiazide Revenue Market Share by Type (2021-2032)
5 Candesartan and Hydrochlorothiazide Market by Application
- 5.1 Candesartan and Hydrochlorothiazide Application Introduction
- 5.1.1 Adults
- 5.1.2 Geriatric
- 5.2 Global Candesartan and Hydrochlorothiazide Sales by Application
- 5.2.1 Global Candesartan and Hydrochlorothiazide Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Candesartan and Hydrochlorothiazide Sales by Application (2021-2032)
- 5.2.3 Global Candesartan and Hydrochlorothiazide Sales Market Share by Application (2021-2032)
- 5.3 Global Candesartan and Hydrochlorothiazide Revenue by Application
- 5.3.1 Global Candesartan and Hydrochlorothiazide Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Candesartan and Hydrochlorothiazide Revenue by Application (2021-2032)
- 5.3.3 Global Candesartan and Hydrochlorothiazide Revenue Market Share by Application (2021-2032)
6 Global Candesartan and Hydrochlorothiazide Sales by Region
- 6.1 Global Candesartan and Hydrochlorothiazide Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Candesartan and Hydrochlorothiazide Sales by Region (2021-2032)
- 6.2.1 Global Candesartan and Hydrochlorothiazide Sales by Region (2021-2026)
- 6.2.2 Global Candesartan and Hydrochlorothiazide Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Candesartan and Hydrochlorothiazide Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Candesartan and Hydrochlorothiazide Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Candesartan and Hydrochlorothiazide Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Candesartan and Hydrochlorothiazide Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Candesartan and Hydrochlorothiazide Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Candesartan and Hydrochlorothiazide Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Candesartan and Hydrochlorothiazide Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Candesartan and Hydrochlorothiazide Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Candesartan and Hydrochlorothiazide Revenue by Region
- 7.1 Global Candesartan and Hydrochlorothiazide Revenue by Region
- 7.1.1 Global Candesartan and Hydrochlorothiazide Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Candesartan and Hydrochlorothiazide Revenue by Region (2021-2026)
- 7.1.3 Global Candesartan and Hydrochlorothiazide Revenue by Region (2027-2032)
- 7.1.4 Global Candesartan and Hydrochlorothiazide Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Candesartan and Hydrochlorothiazide Revenue (2021-2032)
- 7.2.2 North America Candesartan and Hydrochlorothiazide Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Candesartan and Hydrochlorothiazide Revenue (2021-2032)
- 7.3.2 Europe Candesartan and Hydrochlorothiazide Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Candesartan and Hydrochlorothiazide Revenue (2021-2032)
- 7.4.2 Asia-Pacific Candesartan and Hydrochlorothiazide Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Candesartan and Hydrochlorothiazide Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Candesartan and Hydrochlorothiazide Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 ANI Pharmaceuticals
- 8.1.1 ANI Pharmaceuticals Company Information
- 8.1.2 ANI Pharmaceuticals Business Overview
- 8.1.3 ANI Pharmaceuticals Candesartan and Hydrochlorothiazide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 ANI Pharmaceuticals Candesartan and Hydrochlorothiazide Product Portfolio
- 8.1.5 ANI Pharmaceuticals Recent Developments
- 8.2 Dr. Reddy's Laboratories
- 8.2.1 Dr. Reddy's Laboratories Company Information
- 8.2.2 Dr. Reddy's Laboratories Business Overview
- 8.2.3 Dr. Reddy's Laboratories Candesartan and Hydrochlorothiazide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Dr. Reddy's Laboratories Candesartan and Hydrochlorothiazide Product Portfolio
- 8.2.5 Dr. Reddy's Laboratories Recent Developments
- 8.3 MACLEODS
- 8.3.1 MACLEODS Company Information
- 8.3.2 MACLEODS Business Overview
- 8.3.3 MACLEODS Candesartan and Hydrochlorothiazide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 MACLEODS Candesartan and Hydrochlorothiazide Product Portfolio
- 8.3.5 MACLEODS Recent Developments
- 8.4 Prinston Pharmaceutical
- 8.4.1 Prinston Pharmaceutical Company Information
- 8.4.2 Prinston Pharmaceutical Business Overview
- 8.4.3 Prinston Pharmaceutical Candesartan and Hydrochlorothiazide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Prinston Pharmaceutical Candesartan and Hydrochlorothiazide Product Portfolio
- 8.4.5 Prinston Pharmaceutical Recent Developments
- 8.5 Zydus Pharmaceuticals
- 8.5.1 Zydus Pharmaceuticals Company Information
- 8.5.2 Zydus Pharmaceuticals Business Overview
- 8.5.3 Zydus Pharmaceuticals Candesartan and Hydrochlorothiazide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Zydus Pharmaceuticals Candesartan and Hydrochlorothiazide Product Portfolio
- 8.5.5 Zydus Pharmaceuticals Recent Developments
- 8.6 AstraZeneca
- 8.6.1 AstraZeneca Company Information
- 8.6.2 AstraZeneca Business Overview
- 8.6.3 AstraZeneca Candesartan and Hydrochlorothiazide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 AstraZeneca Candesartan and Hydrochlorothiazide Product Portfolio
- 8.6.5 AstraZeneca Recent Developments
- 8.7 Mylan
- 8.7.1 Mylan Company Information
- 8.7.2 Mylan Business Overview
- 8.7.3 Mylan Candesartan and Hydrochlorothiazide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Mylan Candesartan and Hydrochlorothiazide Product Portfolio
- 8.7.5 Mylan Recent Developments
- 8.8 TEVA
- 8.8.1 TEVA Company Information
- 8.8.2 TEVA Business Overview
- 8.8.3 TEVA Candesartan and Hydrochlorothiazide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 TEVA Candesartan and Hydrochlorothiazide Product Portfolio
- 8.8.5 TEVA Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Candesartan and Hydrochlorothiazide Value Chain Analysis
- 9.1.1 Candesartan and Hydrochlorothiazide Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Candesartan and Hydrochlorothiazide Production Mode & Process
- 9.2 Candesartan and Hydrochlorothiazide Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Candesartan and Hydrochlorothiazide Distributors
- 9.2.3 Candesartan and Hydrochlorothiazide Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst